{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:32:42Z","timestamp":1700307162092},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1006\/gyno.2001.6121","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T18:50:18Z","timestamp":1032288618000},"page":"216-224","source":"Crossref","is-referenced-by-count":7,"title":["Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study"],"prefix":"10.1006","volume":"81","author":[{"given":"H.Miles","family":"Prince","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Planner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Neesham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Gates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Davison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2001.6121_RF1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2001.6121_RF2","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF4","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.1996.14.12.3074","article-title":"Sequences of topotecan and cisplatin: a phase I, pharmacologic, and in vitro studies to examine sequence dependence","volume":"14","author":"Rowinsky","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1023\/A:1008253314126","article-title":"Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma","volume":"8","author":"Raymond","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2001.6121_RF6","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.1994.12.12.2743","article-title":"Phase I study of topotecan and cisplatin in patients with advanced solid tumours: a cancer and leukemia group B study","volume":"12","author":"Miller","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1179::AID-CNCR23>3.0.CO;2-I","article-title":"Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer","volume":"85","author":"Hainsworth","year":"1999","journal-title":"Cancer"},{"key":"10.1006\/gyno.2001.6121_RF8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.1997.15.1.177","article-title":"Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group sudy","volume":"15","author":"O'Reilly","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF9","first-page":"525a","article-title":"Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy","volume":"18","author":"Tweedy","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF10","first-page":"470a","article-title":"Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer","volume":"18","author":"Jacobs","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/JCO.1998.16.6.2032","article-title":"Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer","volume":"16","author":"Fleming","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF12","first-page":"515a","article-title":"Toxicity of paclitaxel and topotecan with previously untreated extensive small cell lung cancer","volume":"18","author":"Lynch","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF13","first-page":"382a","article-title":"A phase I\/II and pharmacokinetic study of 96 hour infusional topotecan and paclitaxel chemotherapy for relapsed epithelial ovarian cancer","volume":"18","author":"Penson","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF14","first-page":"383a","article-title":"Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel and platinum resistant advanced ovarian cancer","volume":"18","author":"Piver","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF15","first-page":"373a","article-title":"Phase II trial of topotecan combined with cisplatin in squamous and non-squamous cervival cancer: preliminary results","volume":"18","author":"Fiorica","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF16","first-page":"364a","article-title":"Phase I study of topotecan with carboplatin alternating with paclitaxel via a 3 hour infusion in combination with carboplatin in treatment of newly diagnosed ovarian cancer patients","volume":"18","author":"Gordon","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF17","first-page":"366a","article-title":"A phase I study of carboplatin and escalating dose of topotecan in late recurrent ovarian carcinoma","volume":"18","author":"Bolis","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF18","first-page":"209a","article-title":"Phase I study of topotecan plus carboplatin\/paclitaxel in advance solid tumours","volume":"18","author":"Dunphy","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.1999.17.3.741","article-title":"Back to the future: multiagent chemotherapy in ovarian cancer revisited","volume":"17","author":"Cannistra","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.1992.10.3.464","volume":"10","author":"Shea","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.1994.12.5.1012","article-title":"Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cell in patients receiving multiple cycles of high-dose chemotherapy","volume":"12","author":"Shea","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/jnci\/84.24.1935","article-title":"Rapid delivery of multiple courses of high-dose chemotherapy with granulocyte colony-stimulating factor and peripheral blood derived hematopoietic progenitor cells","volume":"84","author":"Crown","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2001.6121_RF23","first-page":"6137","article-title":"Simultaneous dose-escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial","volume":"54","author":"Fennelly","year":"1994","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2001.6121_RF24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bmt.1701659","article-title":"Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I\/II study in advanced ovarian cancer","volume":"23","author":"Wandt","year":"1999","journal-title":"Bone Marrow Transplantation"},{"key":"10.1006\/gyno.2001.6121_RF25","first-page":"S2-26","article-title":"Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer","volume":"24","author":"Fennelly","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF26","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.1998.16.5.1852","article-title":"Phase II study of \u201cdose-dense\u201d high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer","volume":"16","author":"Aghajanian","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF27","first-page":"99","article-title":"High-dose chemotherapy in ovarian carcinaoma","volume":"26","author":"Herrin","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.1994.12.1.176","article-title":"Phase I clinical and pharmacokinetic study of high dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma","volume":"12","author":"Stiff","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0140-6736(92)91404-V","article-title":"Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer","volume":"340","author":"Kaye","year":"1992","journal-title":"Lancet"},{"key":"10.1006\/gyno.2001.6121_RF30","first-page":"414","article-title":"Characteristics of cisdiaminedochloroplatinum (II)-resistant human ovarian cancer cell line and its evaluation in platinum analogues","volume":"47","author":"Behrens","year":"1987","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2001.6121_RF31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.1987.5.5.756","article-title":"Dose intensity analysis of chemotherapy regimens in ovarian carcinoma","volume":"5","author":"Levin","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/oxfordjournals.annonc.a058516","article-title":"A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles","volume":"4","author":"Murphy","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2001.6121_RF33","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.1998.16.7.2426","article-title":"Randomised study of dose-intensity with single agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group","volume":"16","author":"Gore","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.1997.15.1.193","article-title":"Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group Study","volume":"15","author":"Jakobsen","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF35","first-page":"280","article-title":"A randomized trial of paclitaxel at 2 dose levels and filgrastim at 2 doses in platinum pretreated epithelial ovarian cancer: a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study","volume":"15","author":"Omura","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF36","first-page":"2268","article-title":"Effect of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analog","volume":"54","author":"Hendricks","year":"1992","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2001.6121_RF37","first-page":"467","article-title":"In vitro and in vivo effects of clinically important camptothecin analogues in multidrug resistant cells","volume":"5","author":"Mattern","year":"1993","journal-title":"Oncology Res"},{"key":"10.1006\/gyno.2001.6121_RF38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.1994.12.2.241","article-title":"Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer","volume":"12","author":"Schiller","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase 1 inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF40","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1200\/JCO.1996.14.4.1224","article-title":"Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumours","volume":"14","author":"Rowinsky","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1445-5994.1996.tb01925.x","article-title":"Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute","volume":"26","author":"Millward","year":"1996","journal-title":"Aust NZ J Med"},{"key":"10.1006\/gyno.2001.6121_RF42","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1701308","article-title":"Peripheral blood CD34-positive cell count reliably predicts autograft yield","volume":"22","author":"Chapple","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1006\/gyno.2001.6121_RF44","first-page":"269","article-title":"Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens","volume":"6","author":"Cheng","year":"1994","journal-title":"Oncol Res"},{"key":"10.1006\/gyno.2001.6121_RF45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/86.20.1517","article-title":"Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design","volume":"86","author":"Chou","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2001.6121_RF46","first-page":"210a","article-title":"Impact of carboplatin sequence on myelosuppression and systemic exposure of topotecan in small cell lung cancer","volume":"18","author":"Faucette","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF47","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.1997.15.4.1309","article-title":"High-dose chemotherapy with autologous transplantation for persistant\/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients","volume":"15","author":"Stiff","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF48","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.1997.15.4.1302","article-title":"High-dose chemotherapy with hematopoietic rescue on patients with stage III to IV ovarian cancer: long-term results","volume":"15","author":"Legros","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF49","first-page":"227","article-title":"High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France","volume":"5","author":"Viens","year":"1990","journal-title":"Bone Marrow Transplantation"},{"key":"10.1006\/gyno.2001.6121_RF50","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.bmt.1701398","article-title":"High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell resuce in patients with advanced stage III\/IV ovarian cancer","volume":"22","author":"Holmberg","year":"1998","journal-title":"Bone Marrow Transplantation"},{"key":"10.1006\/gyno.2001.6121_RF51","unstructured":"Stiff, P, J, Shpall, E, J, Tan, Set al. : High dose combination chemotherapy and bone marrow rescue for ovarian carcinoma: current status in the United States. Autologous marrow and blood transplantation. Dicke KA, Keating A, editors. Proceedings of the Seventh International Symposium, Arlington, Texas. Arlington, TX: The Cancer Treatment Research and Educational Institute,1995:453\u20138."},{"key":"10.1006\/gyno.2001.6121_RF52","unstructured":"Mulder, N, H, Aalders, J, G, Mulder, P, OMet al. : High-dose chemotherapy with autologous bone marrow transplantation in ovarian cancer. Autologous marrow and blood transplantation, In: Dicke KA, Keating A, editors. Proceedings of the Seventh International Symposium, Arlington, TX: The Cancer Treatment Research and Educational Institute,1995:459\u201364."},{"key":"10.1006\/gyno.2001.6121_RF53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.1999.17.3.747","article-title":"Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administerd intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer","volume":"17","author":"Herben","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF54","first-page":"564a","article-title":"Topotecan and high-dose cyclophosphamide: salvage therapy for pediatric solid tumors","volume":"18","author":"Kushner","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF55","first-page":"44a","article-title":"Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer","volume":"18","author":"Donato","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF56","first-page":"373a","article-title":"Phase I\/II trial of multicycle paclitaxel\/carboplatin\/topotecan\/etoposide\/thiotepa with peripheral blood progenitor support in ovarian cancer","volume":"18","author":"Rella","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF57","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.1996.14.3.800","article-title":"Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer","volume":"14","author":"Lind","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF58","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.1999.17.7.2198","article-title":"Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral blood stem cells","volume":"17","author":"Schilder","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF59","first-page":"75a","article-title":"Phase I study of multiple cycles of high dose topotecan, carboplatin and paclitaxel with peripheral blood stem cell support","volume":"17","author":"Schilder","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF60","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1995.13.7.1768","article-title":"Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion","volume":"13","author":"van Warmerdam","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6121_RF61","first-page":"329","article-title":"Phase I trial of topotecan administered by 24-hour infusion without and with G-CSF","volume":"34","author":"Abbruzzese","year":"1993","journal-title":"Proc AACR"},{"key":"10.1006\/gyno.2001.6121_RF62","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6121_RF63","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801961219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801961219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T07:29:00Z","timestamp":1557300540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825801961219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S0090825801961219"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2001.6121","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}